PFGC 2021 Highlights Podcast

 

In this episode (20:17 min), Medicom’s correspondent covers 6 presentations from the 9th International Congress, Psoriasis: from Gene to Clinic which was held as a hybrid event based in London, Thursday 9 December – Saturday 11 December 2021.

The topics discussed are:

1. Spesolizumab treatment downregulates IL-36 gene expression in GPP
   Gene expression patterns differed between lesional and non-lesional skin of patients with generalised pustular psoriasis (GPP) with an upregulation, especially in the IL-36 gene family. These expressions were significantly decreased after treatment with spesolimab in the Effisayil 1 trial.
2. Ixekizumab: confirmed efficacy in psoriatic patients with diabetes
   In a post-hoc investigation of the phase 3 UNCOVER trials, ixekizumab treatment resulted in high proportions of Psoriasis Area and Severity Index (PASI) amelioration in diabetic participants. Therapy did not change lipid profile, blood pressure, and BMI.
3. Psoriasis is associated with a higher cancer risk
   A large registry study showed that psoriasis is linked with a higher cancer risk overall and in specific sites, particularly in severe disease. In addition, psoriasis was associated with several cancers beyond those currently regarded as connected.
4. Guselkumab shows highest drug survival among systemic treatments
   In a comparison of 5 commonly used systemic treatments for psoriasis, guselkumab demonstrated the highest drug survival and adalimumab the lowest at 1 and 2 years. If the drug was discontinued due to ineffectiveness of treatment, previous lines of biologics also influenced drug survival.
5. PsA: Upregulation of genes related to neutrophils and monocytes
   An analysis of gene profiles of patients with active psoriatic arthritis (PsA) compared with healthy controls showed that genes related to neutrophils, monocytes, eosinophils, and macrophages are upregulated. Therapy with guselkumab led to a down-regulation of these genes towards a normalisation of whole blood transcriptomic signatures
6. Second shot COVID-19 vaccine urgently needed for patients treated with immunomodulators
   In 17% of patients with immune-mediated inflammatory diseases (IMID) on immunomodulating treatment, no seroconversion occurred after their first dose of SARS-CoV-2 vaccination. Reassuringly, 99% developed antibodies after their second dose.

Enjoy listening!

Copyright ©2021 Medicom Medical Publisher



Posted on 22 December 202127 June 2024